Immutep receives feedback from the Spanish AEMPS for TACTI-004 trial

Immutep announces it has received positive feedback from the Spanish Agency for Medicines and Health Products, AEMPS, Competent Authority regarding the Company’s upcoming TACTI-004 Phase III trial of eftilagimod alpha for first line treatment of metastatic non-small cell lung cancer. Immutep SVP, Regulatory & Strategy, Christian Mueller commented: “We continue to be pleased with our discussions with regulatory bodies around the world regarding our upcoming pivotal TACTI-004 trial and are thankful for the positive feedback and constructive guidance received by AEMPS. Spain, a member of the EMA’s Committee for Medicinal Products for Human Use (CHMP), represents an important region given the relatively large number of institutions that participated in our TACTI-002 Phase II study evaluating efti in combination with anti-PD-1 therapy in first line non-small cell lung cancer.”